KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageDebt RatioDebt to EquityEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInterest Coverage RatioInventory AverageInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on SalesTimes Interest Earned

Halozyme Therapeutics (HALO) Equity Average (2016 - 2025)

Halozyme Therapeutics (HALO) has disclosed Equity Average for 15 consecutive years, with $276.4 million as the latest value for Q4 2025.

  • On a quarterly basis, Equity Average fell 32.31% to $276.4 million in Q4 2025 year-over-year; TTM through Dec 2025 was $276.4 million, a 32.31% decrease, with the full-year FY2025 number at $206.3 million, down 7.82% from a year prior.
  • Equity Average was $276.4 million for Q4 2025 at Halozyme Therapeutics, down from $418.3 million in the prior quarter.
  • In the past five years, Equity Average ranged from a high of $423.0 million in Q1 2025 to a low of $93.7 million in Q2 2021.
  • A 5-year average of $236.9 million and a median of $214.7 million in 2021 define the central range for Equity Average.
  • Peak YoY movement for Equity Average: tumbled 60.81% in 2023, then skyrocketed 223.41% in 2025.
  • Halozyme Therapeutics' Equity Average stood at $239.3 million in 2021, then tumbled by 44.26% to $133.4 million in 2022, then increased by 24.81% to $166.5 million in 2023, then surged by 145.21% to $408.3 million in 2024, then tumbled by 32.31% to $276.4 million in 2025.
  • Per Business Quant, the three most recent readings for HALO's Equity Average are $276.4 million (Q4 2025), $418.3 million (Q3 2025), and $407.5 million (Q2 2025).